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Selected mutations in the human 4 or 2 neuronal nicotinic
acetylcholine receptor subunit genes cosegregate with a partial
epilepsy syndrome known as autosomal dominant nocturnal fron-
tal lobe epilepsy (ADNFLE). To examine possible mechanisms un-
derlying this inherited epilepsy, we engineered two ADNFLE mu-
tations (Chrna4S252F and Chrna4L264) in mice. Heterozygous
ADNFLE mutant mice show persistent, abnormal cortical electro-
encephalograms with prominent delta and theta frequencies, ex-
hibit frequent spontaneous seizures, and show an increased sen-
sitivity to the proconvulsant action of nicotine. Relative to WT,
electrophysiological recordings from ADNFLE mouse layer IIIII
cortical pyramidal cells reveal a >20-fold increase in nicotine-
evoked inhibitory postsynaptic currents with no effect on excita-
tory postsynaptic currents. i.p. injection of a subthreshold dose of
picrotoxin, a use-dependent -aminobutyric acid receptor antag-
onist, reduces cortical electroencephalogram delta power and
transiently inhibits spontaneous seizure activity in ADNFLEmutant
mice. Our studies suggest that the mechanism underlying ADNFLE
seizures may involve inhibitory synchronization of cortical net-
works via activation of mutant 4-containing nicotinic acetylcho-
line receptors located on the presynaptic terminals and somato-
dendritic compartments of cortical GABAergic interneurons.
cortex  GABAegic interneuron  nicotinic acetylcholine receptor
Epilepsy is a common neurological disorder affecting 1% ofthe population worldwide. Over the past decade, several
idiopathic epilepsies have been identified that show single-gene
inheritance. Autosomal dominant nocturnal frontal lobe epi-
lepsy (ADNFLE) was the first idiopathic epilepsy for which
specific mutations were described (1). Segregation and subse-
quent linkage analyses of ADNFLE families led to the assign-
ment of candidate genetic loci and ultimately to the identifica-
tion of specific mutations. Two of the three loci associated with
this partial epilepsy (ENFL1, 20q13.3 and ENFL3, 1p21) map to
neuronal nicotinic acetylcholine receptor (nAChR) subunit
genes 4 and 2 (CHRNB2), respectively. A candidate gene for
the third locus (ENFL2, 15q24) has not been identified. Con-
siderable clinical and genetic data now provide a strong link
between the ADNFLE syndrome and six mutations located
within the pore-forming, second transmembrane domain of the
4 (S252F, L264, S256L, T265I) and 2 (V287L, V287M)
nAChR subunits (2), as well as a single mutation located in the
third transmembrane domain of the 2 subunit (I312M) (3).
In most patients with ADNFLE, seizure onset occurs during
adolescence with symptoms persisting into adulthood. Affected
individuals typically present without adverse neurological symp-
toms other than seizures, although several reports describe
ADNFLE patients with a concomitant history of psychiatric
problems (4, 5), cognitive deficits (3), or mental retardation (6).
Clinical features of ADNFLE include clusters of brief seizures
that initiate during non-rapid eye movement (NREM) sleep.
Ictal and interictal electroencephalograms (EEGs) are often
uninformative and clinical diagnosis is best achieved by using a
combination of nocturnal video-polysomnography and genetic
analyses (7). Whereas the frontal lobe origin, adolescent onset,
and clusters of nocturnal, hyperkinetic motor seizures are sig-
natures of this disorder, the ADNFLE seizure phenotype shows
incomplete penetrance and can present with (6, 8) or without (4,
9) intra- and interfamilial variation in expressivity.
Given the similarities in clinical symptoms, it has been sug-
gested that a common functional anomaly of mutant 4- and
2-subunit-containing nAChRs underlies ADNFLE. However,
studies in heterologous expression systems designed to discover
a shared, altered property that might explain the neuronal
network dysfunction underlying ADNFLE seizures have lead to
both ‘‘gain-of-function’’ (10–12) and ‘‘loss-of-function’’ (8, 13,
14) models. The effect of stimulating nAChRs (mutant or
otherwise) on cortical network activity is difficult to predict,
hence, insight into the mechanism responsible for neuronal
synchrony and epileptogenesis in ADNFLE must necessarily
come from models that attempt to reconstitute the in vivo
distribution and function of mutant nAChRs. To more fully
understand the pathophysiology and mechanism underlying this
epilepsy, we genetically engineered two mouse strains that
harbor the ADNFLE Chrna4S252F and Chrna4L264 mutant
alleles. The characterization and validation of this mouse model
of ADNFLE should provide an important tool with which to
examine the molecular, cellular, and developmental basis for
epileptogenesis.
Results
Heterozygous and homozygous ADNFLE mutant mouse strains
are viable, show expected gender and Mendelian genotype ratios,
express equal levels of WT and mutant 4 transcripts, and exhibit
no gross neuroanatomical abnormalities (Figs. 5–8, which are
published as supporting information on the PNAS web site).
However, relative to age and gender-matched WT littermates, all
heterozygous Chrna4S252F/wt and Chrna4L264/wt mice show abnor-
mal EEGs, which are characterized by a marked increase in  wave
activity (0.5–4 Hz) (Fig. 1a). Similar results were observed with
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homozygous Chrna4S252F/S252F and Chrna4L264/L264 mice (Fig. 9,
which is published as supporting information on the PNAS web
site). A considerable increase in  wave activity (4–8 Hz) also is
evident in the EEG patterns of Chrna4S252F/wt (Fig. 1a),
Chrna4S252F/S252F, and Chrna4L264/L264 mice (Fig. 9a). Such ab-
normal EEGs were observed 50–80% of the time during every
4-hour recording epoch in Chrna4S252F/wt (n  10) and
Chrna4L264/wt (n  4) mice (Fig. 10, which is published as
supporting information on the PNAS web site).
In addition to abnormal EEGs, heterozygous Chrna4S252F/wt
and Chrna4L264/wt mice exhibit recurrent spontaneous seizures,
which are accompanied by high-amplitude, low-frequency cor-
tical EEG activity (Fig. 1b). Seizure semiology ranges from brief
periods (1–5 s) of behavioral arrest to extended periods (2–60
min) of rhythmic, jerking motion involving all extremities, loss of
balance, and frequent falling to one side (Movie 1, which is
published as supporting information on the PNAS web site). Fig.
1 b and c show sample EEGs obtained from subdural recording
electrodes during spontaneous seizures of Chrna4S252F/wt (n 
10) and Chrna4L264/wt (n  4) mice. Such repetitive EEG
discharges characterized by paroxysmal onset, sudden termina-
tion, and asymmetric rhythmic patterns of spiking activity were
observed during 5.1  3.6% of each 4-hour recording epoch in
Chrna4L264/wt mice and 22.0  11.7% in Chrna4S252F/wt mice.
Similar seizure activity was observed in homozygous
Chrna4S252F/S252F and Chrna4L264/L264 mice, which exhibited
epileptiform activity 21.5  5.4% and 5.7  3.5% of the time,
respectively (Fig. 10b).
Having established that heterozygous Chrna4S252F/wt and
Chrna4L264/wt mice exhibit spontaneous seizures, we sought to
investigate the electrophysiological mechanism underlying epi-
leptogenesis at the level of cortical circuits. Although 4-
containing nAChRs are widely expressed in the vertebrate brain,
altered cholinergic activation of neocortical andor thalamocor-
tical networks may play a central role in the generation of
ADNFLE seizures as EEG recordings from ADNFLE patients
suggest that seizures originate in the frontal lobe of the neocor-
tex (7). Because synaptic activity in pyramidal cells is a major
source of cortical EEG activity, we first examined the effect of
ADNFLE mutations on the synaptic events of layer IIIII
pyramidal cells of the frontal cortex.
Whole-cell voltage-clamp recordings of spontaneous excita-
tory postsynaptic currents and spontaneous inhibitory postsyn-
aptic currents (sIPSCs) were obtained from layer IIIII pyra-
midal cells of WT and Chrna4S252F/wt mouse brain slices (Fig. 2).
There were no significant differences between the excitatory or
inhibitory synaptic events recorded under control conditions in
WT and Chrna4S52F/wt mouse pyramidal cells (Tables 2 and 3,
which are published as supporting information on the PNAS web
site).We next examined whether activation ofWT andADNFLE
mutant nAChRs by nicotine (1 M) results in differential effects
on synaptic currents. Regardless of genotype, nicotine had no
effect on spontaneous excitatory postsynaptic current frequency,
kinetics, or amplitude during 30-s recording periods sampled
during drug perfusion (P 0.05, paired and unpaired t test; Fig.
2 and Table 2). In marked contrast, the effect of nicotine on
IPSCs was dramatically different between WT and ADNFLE
mutant mice. In WT brain slices, nicotine had little effect on
sIPSC frequency or kinetics (Fig. 2, n 6; P 0.05, paired t test;
Table 3), whereas it significantly increased both frequency and
amplitude of sIPSCs inChrna4S252F/wt pyramidal cells (Fig. 2, n
5; P  0.05, paired t test; Table 3). To better resolve the
Fig. 1. Both Chrna4S252F/wt and Chrna4L264/wt mice exhibit abnormal cortical EEGs and show spontaneous, repetitive EEG discharges with paroxysmal onset and
sudden termination. (a) Relative to WT, fast Fourier transform analyses of recordings from awake Chrna4S252F/wt and Chrna4L264/wt mice show a marked increase
in  (0.5–4 Hz) and, in the case of Chrna4S252F/wt mice,  frequencies (4–8 Hz). (b and c) EEG recordings during spontaneous seizures in Chrna4S252F/wt and
Chrna4L264/wt mice. (b) Higher-resolution traces show complex patterns of spike and wave activity with high-amplitude, low-frequency power spectra in
Chrna4S252F/wt mice, and a more asymmetric, diffuse pattern in Chrna4L264/wt mice. (c) The traces show 15 min of continuous EEG data, including the periods
immediately before and after paroxysmal discharges in Chrna4S252F/wt and Chrna4L264/wt mice. Note pre- and postictal spiking in ADNFLE mutant mice and the
sudden onset of clusters of high-amplitude spikes.
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compound effect of nicotine on the frequency, amplitude, and
kinetics of sIPSCs, we measured the mean inhibitory current
(Imean, see Methods) and calculated the effect of nicotine as the
ratio of Imean measured before and after its perfusion (Fig. 3a).
Fitting an -function to the inhibitory Imean allowed us to
determine the latency and decay of the nicotine effect, and these
parameters are approximately proportional to the sensitivity and
desensitization of the nicotine responses, respectively.
On average, the effect of nicotine (1 M) on the inhibitory
Imean (Vh  0 mV) was a 23.4  5.0-fold (n  6) increase over
baseline in Chrna4S252F/wt pyramidal cells. A similar treatment in
WT pyramidal cells increased inhibitory Imean only 2.5 0.4-fold
(n  8; P  0.05, one-way ANOVA; Fig. 3 a–c). Nicotine also
caused large increases in Imean in Chrna4L264/wt pyramidal cells
(20.1 5.6-fold; P 0.05, one-way ANOVA; n 5, Fig. 3b). The
nicotine effects on Imean showed similar decay across genotypes
(, Fig. 3 b and d). The effect of nicotine on Imean did not change
when glutamate receptors were blocked by D-2-amino-5-
phosphonovaleric acid (25 M) and 6-cyano-7-nitroquinoxaline-
2-dione (CNQX) (10 M) (18.2 2.3-fold increase, n 4; P
0.05, unpaired t test; Fig. 3d), indicating that nicotine has little
effect on the excitatory drive onto the interneurons. We also
tested the effects of antagonists to ensure that the effects of
nicotine were mediated by 4-subunit-containing nAChRs. The
nicotine-induced inhibition was insensitive to an antagonist of
7-subunit-containing nAChRs [methyllycaconitine (MLA), 50
nM, n  6, Fig. 3d]. In contrast, perfusion of the 42 nAChR
subtype-selective antagonist dihydro--erythroidine (DHE)
(10 M, n  3) resulted in 90% decrease in the effect of
nicotine on inhibitory Imean (2.20 0.83 vs. 23.4 5.0, P 0.05,
t test assuming unequal variances; Fig. 3d).
Based on combined electrophysiological (15) and molecular
studies (16), the observed increase in inhibitory Imean is very
likely a result of an enhanced nicotine-evoked GABA release
from Chrna4S252F/wt or Chrna4L264/wt-expressing cortical inter-
neurons that form synapses on the somata, axon initial segments,
or dendrites of pyramidal cells. To determine whether nicotine
acts on 4-subunit-containing nAChRs located on GABAergic
interneuron terminals, we measured its effect on miniature
IPSCs (mIPSCs) recorded in the absence of presynaptic Ca2
entry by blocking action potentials with tetrodotoxin (TTX) and
voltage-gated Ca2 channels with cadmium. Perfusion of WT
brain slices with TTX (0.5 M) and CdCl2 (50 M) significantly
decreased the frequency (27%) and amplitude (34%) of
pyramidal cell IPSCs indicating that a large fraction of sIPSCs
are mediated by Ca2 entry into GABAergic terminals (data not
shown). The mIPSCs of WT and Chrna4S252F/wt pyramidal cells
were not significantly different (P  0.05, unpaired t test, Table
1), and addition of nicotine (1 M) did not alter mIPSCs
Fig. 2. Nicotine increases sIPSCs recorded from cortical layer IIIII pyramidal
cells without affecting spontaneous excitatory postsynaptic currents. Voltage
clamp recordings were obtained from WT (a) and Chrna4S252F/wt cortical layer
IIIII pyramidal (b) cells immediately before and during perfusion of ACSF
containing nicotine (1 M, shown by a solid bar). In Chrna4S252F/wt slices,
nicotine induced a net increase in pyramidal cell inhibitory Imean (Vh  0 mV)
of 23.4  5.0-fold (n  6), whereas for WT, the Imean ratio was 2.5  0.4-fold
(n 9). Gaps in the current traces indicate times at which membrane seal tests
were performed, and expanded traces are shown for periods corresponding to
perfusion with ACSF alone (‚) or ACSF plus nicotine (Œ).
Fig. 3. The pharmacology and kinetics of nicotine-enhanced, cortical pyra-
midal cell sIPSCs are similar in brain slices prepared from both Chrna4S252F/wt
and Chrna4L264/wt mice. (a) Recordings from WT (lower trace; n  8) and
Chrna4S252F/wt (upper trace; n  6) cortical layer IIIII pyramidal cells immedi-
ately before and during perfusion of ACSF containing nicotine. Averages of
the recordings were fit to an  function (smooth solid line), with the shaded
area corresponding to the SEM. (b) The fitted sIPSC mean values (Imean,
baseline subtracted) in WT (n  8), Chrna4S252F/wt (n  6), and Chrna4L264/wt
(n5) cortical pyramidal cells before and during perfusion of ACSF containing
nicotine (1M at time 0 s, arrow). (c) The normalized sIPSC ratios (peak current
in the presence of 1 M nicotine divided by control responses) for WT (n 8),
Chrna4S252F/wt (n 6), and Chrna4L264/wt (n 5) cortical pyramidal cells. *, P
0.05, one-way ANOVA. (d) The fitted sIPSC mean values (Imean, baseline sub-
tracted) in Chrna4S252F/wt cortical pyramidal cells after perfusion of nicotine (1
M at time 0 s, arrow) in the presence of 50 nM methyllycaconitine (MLA) (n
6), 10 M dihydro--erythroidine (DHE) (n  3), or a mixture of 10 M
6-cyano-7-nitroquinoxaline-2-dione (CNQX) and 25 M APV (n  4). The
dotted line represents the response to nicotine alone.
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frequency and kinetics in the WT (P  0.05, paired t test, n 
4; Table 1). Even when presynaptic voltage-gated Na and Ca2
channels were blocked, nicotine significantly increased the am-
plitude (17%) and frequency (42%) of mIPSCs in Chrna4S252F/wt
brain slices (P  0.05, paired t test; n  7; Table 1). The
combined effect of nicotine on mIPSC frequency and amplitude
resulted in an increased inhibitory Imean of 3.38 0.57-fold (n
8) in the absence of any voltage-gated Na and Ca2 entry into
the terminals. Thus, a considerable fraction of ADNFLEmutant
4-subunit-containing nAChRs are located on presynaptic ter-
minals of cortical GABAergic interneurons and elevate presyn-
aptic Ca2 levels.
To explore the relationship between increased GABA-
mediated IPSCs, abnormal cortical EEGs, and seizure activity in
ADNFLE mutant mice, we examined the effect of picrotoxin
(PTX), a use-dependent antagonist of GABAA receptors, on the
EEG and spontaneous seizures in Chrna4S252F/wt mice. The data
in Fig. 4 reveal that in WT mice, i.p. injection of low-dose PTX
(0.1 mgkg) has little effect on the cortical EEG, relative 
power, and percentage of time exhibiting  wave activity (Fig. 4
a, c, and d) and shows no proconvulsant activity (Fig. 4e).
However, in Chrna4S252F/wt mice, this subthreshold dose ‘‘nor-
malizes’’ the baseline EEG (Fig. 4b), decreases the relative
power and time-expressing  wave activity (Fig. 4 c and d), and
completely inhibits spontaneous seizure activity (Fig. 4e).
Discussion
Whereas genetic factors contribute to 40% of all human
epilepsies,30 idiopathic epilepsy syndromes show amonogenic
mode of inheritance and, of those, only 12 disorders have been
associated with a specific genetic locus (17). Here, we report two
murine models of a human familial channelopathy linked to
epilepsy. In vivo, the Chrna4S252F and Chrna4L264 ADNFLE
mutations both produce abnormal cortical EEG patterns, inter-
ictal spiking, and recurrent seizure activity in mice. The interictal
spiking and spontaneous seizures seen in bothChrna4S252F/wt and
Table 1. Nicotine increases frequency, amplitude, and alters response kinetics of mIPSCs
in pyramidal cell neurons of Chrna4S252Fwt mice
Measurement
WT Chrna4S252F/wt
Control Nicotine Control Nicotine
Frequency, per sec 20.1  5.0 18.4  4.3 16.8  1.4 29.0  2.8*
Peak amplitude, pA 15.2  1.5 13.0  1.4 16.1  0.8 19.5  0.9*
Rise time 10–90, ms 0.84  0.05 1.03  0.07 0.86  0.05 0.89  0.06
decay, ms 6.83  0.38 7.08  0.36 6.72  0.13 7.43  0.26*
Whole-cell voltage clamp recordings (Vh 0 mV) were obtained from frontal cortex layer IIIII pyramidal cells
in the presence of APV (25 M), CNQX (10 M), CdCl2 (50 M), and TTX (0.5 M). Events were detected and
analyzed in 60-s segments. Values represent the mean SEM. Comparisons were made between nicotine-treated
(1M) WT (n 4) and Chrna4S252Fwt (n 7) brain slices. Values with asterisks represent P 0.05 by using a paired
t test. No statistical differences were found between control values of both genotypes (P 0.05, unpaired t test).
Fig. 4. Chrna4S252F/wt mice have abnormal cortical EEGs with persistent  (0.5–4 Hz) activity, which is decreased by low-dose PTX. (a) WT EEGs do not significantly
differ between pre- and post-PTX (0.1 mgkg, i.p.) treatment. (a and b) FFT analyses of baseline recordings from WT (n 6) (a) and Chrna4S252F/wt (n 6) (b) mice
illustrate the increase in  power in Chrna4S252F/wt mice. FFT analysis also demonstrates the decrease in  activity in Chrna4S252F/wt mice (n  6) after treatment
with PTX. PTX did not have an effect on the fast Fourier transform in WT mice (n 6). (c) Compared with untreated controls, the relative contribution of  activity
is decreased after administration of PTX in Chrna4S252F/wt mice, with no significant difference seen in WT mice. (d) In addition to a decrease in power, the amount
of time exhibiting  wave activity was decreased in the 60-min period after PTX administration compared with the 60-min period immediately before PTX
administration. Picrotoxin did not have a significant effect on the amount of time WT mice exhibited  activity. (e) Low-dose PTX completely eliminates
spontaneous seizures in Chrna4S252F/wt mice during the 60 min immediately after PTX injection.
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Chrna4L264/wt mice argue that these mutations are sufficient to
cause ADNFLE in humans. In addition, heterozygous ADNFLE
mice are considerably more sensitive to nicotine-induced sei-
zures, show shorter latencies to seizure onset, and exhibit longer
seizure durations than their WT littermates (Fig. 11, which is
published as supporting information on the PNAS web site).
Together with the marked stimulation by nicotine of pyramidal
cell sIPSCs inChrna4S252F/wt andChrna4L264/wt mice, our results
suggest that ADNFLE seizure etiology and altered cortical EEG
patterns may involve an increased response to acetylcholine.
Cholinergic afferents, which arise principally from the basal
forebrain, innervate cholinoceptive neurons in all layers of the
rodent frontal cortex and are especially prominent in layers II
and III of the human cortex. Whereas rodent cortical layer IIIII
and V pyramidal neurons are not directly depolarized by nico-
tinic cholinergic agonists (16, 18, 19), selected subtypes of
cortical interneurons express functional nAChRs assembled
from 4 and 2 subunits (with or without 5) or 7 subunits (16,
20). Inhibitory interneurons release GABA and have been
implicated in nicotine-induced hippocampal seizures (21), as
well as in models of cortical or hippocampal pathophysiology
that result from nAChR activation, modulation of GABAergic
tone, and subsequent inhibition or disinhibition of neuronal
networks (15). It remains to be determined which subclass of
cortical interneurons is responsible for the increased GABAer-
gic drive onto layer IIIII pyramidal cells. In rats,96% of layer
I interneurons express both 42 and 7 nAChR subtypes.
However, it’s unlikely that they play a direct role as nicotinic
stimulation of layer I interneurons leads to an action potential-
dependent increase in layer IIIII interneuron sIPSC frequency,
with no effect on layer IIIII pyramidal cells (20). In layer IIIII,
42 nAChRs (with or without 5) are found in a high per-
centage of regular (63%) and irregular-spiking (77%) interneu-
rons, the majority of which (70%) coexpress vasoactive intes-
tinal peptide and cholecystokinin (16). Such interneurons
innervate adjacent pyramidal cells and are candidates for the
nicotine-evoked increase in inhibition. Layer V low-threshold
spiking interneurons, whose axonal arbors project upwards to
layers IIIII, also express nAChRs and could likewise contribute
to the nicotine-enhanced sIPSC frequency (22). Ultimately, the
use of paired recordings and detailed electrophysiological and
anatomical studies should permit the identification of interneu-
rons involved in the altered effects of acetylcholine (ACh).
As described for a variety of nocturnal epilepsy syndromes,
ADNFLE seizures initiate exclusively or predominantly during
NREM sleep (23). Moreover, in patients with partial epilepsies,
NREM sleep (notably stage 2) potentiates, whereas REM sleep
inhibits, interictal epileptiform discharges and propagation of
focal seizures (24). At this time, we do not know the relationship
between sleep-wake state and seizure onset in ADNFLE mice.
Unfortunately, vigilance and sleep-staging algorithms heavily
rely on EEG patterns to distinguish periods of wakefulness from
REM and NREM sleep. Hence, the nearly continuous, abnor-
mal cortical  and  activities seen in Chrna4S252F/wt and
Chrna4L264/wt ADNFLE mice confound analyses that would
unequivocally establish a temporal relationship between slow
wave sleep, onset of paroxysmal EEG discharges, and seizures.
Establishing whether aberrant signaling within corticothalamic
circuits contributes to epileptogenesis in ADNFLE and docu-
menting the precise effect(s) of mutant 4-subunit-containing
nAChRs on network dynamics in vivo will require additional
electrophysiological experiments.
Rather than demonstrating a failure of GABAergic inhibition
in ADNFLE mice, our EEG and electrophysiological data are
consistent with a model of epileptogenesis in which ACh signif-
icantly enhances cortical GABAergic transmission. An essential
feature of our model (see Fig. 12, which is published as sup-
porting information on the PNAS web site) is that asynchro-
nously firing layer IIIII pyramidal cells will be synchronized
after recovery from a large GABAergic inhibition triggered by
cholinergic activation of mutant nAChRs. The effect of PTX on
cortical EEG and spontaneous seizure activity suggests that
activation of GABAA receptors per se could lead to increased
network synchrony and, thereby, contribute to ictogenesis in this
murine model of ADNFLE. The idea of establishing neuronal
synchrony via inhibition has substantial experimental support.
For example, two hippocampal pyramidal cells connected to the
same GABAergic interneuron readily synchronize their firing
after recovering from the inhibition evoked by the interneuron
(25). Also, in the hippocampus, ACh-dependent activation of
interneurons produces inhibition of pyramidal cells followed by
rebound spiking (26), and endogenous cortical ACh recently has
been shown to enhance synchronized interneuron activity via
activation of 42 nAChRs (27). Importantly, in human focal
cortical dysplasia tissue in vitro ictal activity is initiated via a
synchronization mechanism that requires sustained activation of
GABAA receptors (28). We propose, then, that an ACh-
dependent sudden increase in GABAergic inhibition contributes
to epileptogenesis through inhibitory resetting of synchroniza-
tion. Possible alternative GABA-mediated mechanisms include
direct excitatory effects of axo-axonic interneurons on layer
IIIII pyramidal cells (29) or pyramidal cell depolarization after
intense GABAA receptor activation and changes in the GABA
reversal potential (30).
In summary, our data show that both ADNFLE Chrna4S252F
and Chrna4L264 mutations are dominant and cause abnormal
cortical EEGs, interictal spiking, and recurrent seizures in
heterozygous mice harboring either of these mutations. The
ameliorative effect of low-dose PTX on cortical EEG patterns
and suppression of spontaneous seizures in Chrna4S252F/wt mice
provides compelling evidence for enhanced GABAergic func-
tion in ADNFLE. Although many details of epileptogenesis,
including the possible involvement of noncortical neuronal
circuits, remain to be examined in this mouse model, it seems
clear that a number of important and intriguing questions related
to ANFLE now can be addressed (2). ADNFLE mutations
change the physiology of the brain in ways that allow it to
function normally most of the time, but also render it capable of
recurrent seizures. Future cellular and systems-level analyses of
mutant and WT mice should help identify all possible causative
factors and clarify the pathophysiological mechanisms underly-
ing the complete ADNFLE syndrome.
Experimental Procedures
Genetic Engineering of ADNFLEMutantMice.Genetic engineering of
the ADNFLE mice is described in Fig. 5. All experiments were
carried out under protocols approved by the University of
California, Los Angeles Chancellor’s Animal Research Com-
mittee. Mutant mice and other materials prepared during this
study may be obtained upon request.
Electroencephalogram Recordings. A subdural cortical EEG re-
cording electrode was placed under the skull (2.8 mm anterior to
bregma, 1.5 mm lateral to the midline) of age-matched, adult
male (P  90) mice, and the electrode was fixed to the skull by
using dental cement. EEG recordings (band-pass-filtered be-
tween 0.1 and 200 Hz, 8-pole Bessel; Frequency Devices, Hav-
erhill, MA) were acquired for 4–8 h daily for up to 2 weeks and
were sampled at 1 kHz by using an in-house LabView-based
(National Instruments, Austin, TX) analysis program. Electro-
graphic seizure events were defined as changes in the amplitude
and frequency of the EEG activity, and the software measured
their duration. Seizure susceptibility consisted of cumulative
time seizing expressed as a percentage of the total recording time
and the average duration of individual electrographic events.
The percentage of time seizing was calculated as the cumulative
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time of all seizure activity during the recording period divided by
the total time of the recording period. The durations of indi-
vidual electrographic events were measured between the start of
the repetitive EEG pattern and the return of the EEG spectrum
to baseline. PTX (0.1 mgkg, i.p.) was administered after 60 min
of baseline EEG recording and continued for 60 min after PTX
administration. EEGs were compared between the 60 min
pre-PTX administration and the 1-h post-PTX administration
only. Statistical analysis was determined by using ANOVA.
Brain Slice Preparation, Electrophysiological Recordings, and Data
Acquisition.Adult male mice (2–4 months old) were anesthetized
with halothane, and the brain was removed and placed in
ice-cold artificial cerebrospinal f luid (ACSF) containing 126
mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 1.25 mM
NaH2PO4, 26 mM NaHCO3, and 10 mM D-glucose (pH 7.3–7.4)
when aerated with 95% O2 and 5% CO2. Frontal lobe coronal
slices, 350 m thick, were cut with a vibratome in ACSF
containing 3 mM kynurenic acid. Slices were stored in ACSF in
an interface chamber at 32°C for at least 1 h before being
transferred to the recording chamber. Frontal cortex layer IIIII
pyramidal cells were identified visually by using video micros-
copy and recorded with an Axopatch 200B amplifier (Axon
Instruments, Foster City, CA). Microelectrodes (1–3 M) con-
tained 140 mM cesium-methylsulfonate, 10 mM Hepes, 0.2 mM
EGTA, 5 mM NaCl, 2 mM MgATP, 0.2 mM NaGTP (271
mOsm, pH 7.29). Series resistance and whole-cell capacitance
were estimated from fast transients evoked by a 5 mV voltage
command step by using a lag value of 7 s and then compensated
to 70–80%. Recordings were discontinued if series resistance
increased by 25% through an experiment or if it reached 20
M at any time during the experiment. All recordings were
low-pass-filtered at 3 KHz (8-pole Bessel), digitized online at 10
KHz, and stored on videotape. Data were acquired, and spon-
taneous inhibitory and excitatory events were detected by using
custom-written LabView-based software. All events were de-
tected in 30–60 sec segments. Event frequency, peak amplitude,
10–90% rise time, and weighted decay time constant (decay)
values were measured. Statistical significance was determined by
using the t test (paired or unpaired assuming unequal variances)
or by ANOVAwith a Tukey’s HSD post hoc test when the means
of more than two groups were compared. The level of signifi-
cance was set to P  0.05.
Effect of Nicotine on Mean Inhibitory Current (Imean). Imean was
determined by using a macro running under IGOR Pro version
5.02 (WaveMetrics, Lake Oswego, OR). Briefly, the entire
digitized recording was loaded, and seal tests were deleted. An
all-point amplitude histogram was plotted for every 50,000
points (5 s) and smoothed, obtaining a distribution skewed in the
direction of synaptic events. A Gaussian was fit to the part of the
distribution that was not skewed (representing the baseline
current and its noise), and the peak of this Gaussian was taken
as the mean baseline current for the epoch. All baseline mean
values were plotted, and linear trends were subtracted to nor-
malize the mean baseline current to 0 pA. After baseline
normalization, the cumulative sum of 10,000 data points (1 s) was
calculated and divided by the number of points in that segment
of time. Points on either side of the baseline (baseline noise)
summed to 0, whereas anything above or below baseline summed
to yield Imean. An  function was fitted to Imean obtaining the
peak, latency, and decay of the nicotine effect in every cell. The
equation used was as follows: Imean (t)  A 	 [(t 
 to)] 	 exp
[1 
 (t 
 to)]  y, where A is the peak amplitude, to is the
latency,  is the decay, and y is the control base line. The Imean
ratio was determined by dividing the peak amplitude of Imean
during the nicotine effect by the Imean recorded before perfusion
of nicotine.
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